SAB Biotherapeutics (SABS) Return on Capital Employed (2021 - 2026)

SAB Biotherapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 28.98% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 10527.0% year-over-year to 28.98%; the trailing twelve-month figure through Mar 2026 stood at 28.98% (up 10527.0% YoY), and the FY2025 full-year result was 50.04%, up 2646.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 28.98%, up from 29.23% in the prior quarter.
• The five-year high for Return on Capital Employed was 9.15% in Q3 2023, with the low at 178.37% in Q2 2025.
• Historically, Return on Capital Employed has averaged 62.39% across 5 years, with a median of 51.7% in 2022.
• Annual changes were most pronounced in 2025 — Return on Capital Employed sank 10086 bps — and 2026, when it surged 10527 bps.
• SAB Biotherapeutics' Return on Capital Employed stood at 10.71% in 2022, then sank by 685 bps to 84.0% in 2023, then decreased by 25 bps to 104.62% in 2024, then jumped by 72 bps to 29.23% in 2025, then increased by 1 bps to 28.98% in 2026.
• The last three Return on Capital Employed figures came in at 28.98% (Q1 2026), 29.23% (Q4 2025), and 44.99% (Q3 2025), per Business Quant data.